Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 66.25p 65.50p 67.00p - - - 0 06:33:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.7 -7.9 -9.3 - 45.31

Avacta Share Discussion Threads

Showing 3501 to 3524 of 3525 messages
Chat Pages: 141  140  139  138  137  136  135  134  133  132  131  130  Older
DateSubjectAuthorDiscuss
17/11/2017
09:20
Agree that both Avacta and FinnCap should be doing more to stimulate interest ... either that or not paying to put on such events (time after the AGM would suffice for many). I work part time in medical research these days, and it's fair to say that I'm genuinely excited (as a human being) at some of the things they are doing, whether I as a shareholder get to share in the spoils when they succeed, one can only hope so.
the drewster
17/11/2017
09:00
Yup agreed - thanks for the meeting feedback, i havent yet read but will do so.
escapetohome
17/11/2017
08:57
Pharma is ALWAYS slow. For many PIs it's too slow. Potential rewards remain truly staggering, so I'm staying put. If you want stocks that move every day, pharma isn't really where you should be playing. Up to 2017, just about every scientific objective to de-risk the platform has been achieved, yet the market doesn't value any of it. When it finally happens, I think it will be spectacular, but the "when" bit is for crystal ball gazers only. If you believe, then keep on buying, if you don't, then don't.
the drewster
17/11/2017
08:56
Drewster, Thanks for your feedback, but you can't really defend Finncap or Avacta for the low turnout at the presentation. If Finncap could only get three to their own event they are simply not promoting the company and the Avacta management should do something about that. A group of students could get more than that to a startup meeting! The 85% of institutional investors you refer to were not brought in by Finncap and there is a seller out there. Was that discussed?
lantanatony
17/11/2017
08:05
There aren't that many PIs as 85% plus of the shares live with institutions. We actually discussed the merit of organising such a meeting when so few attended - selfishly, it was great, as I got to ask every question I had, and discussed the science in some detail, but Alastair while keen to give PIs the same briefing as the IIs, agreed that if the events didn't attract any interest, there was little point organising them - we have been warned!
the drewster
17/11/2017
04:30
Apologies ,my previous post should have read....any broker that can't get more than three people to an event in London for one of its clients must have lost interest. (Must get some glasses)
lantanatony
16/11/2017
21:29
I seriously don't wish to gloat but if Finncap can only get three people to a much publicised event,Then all of us must question their merit. They became Avacta's brokers when the shares were over a pound. Since then their performance has been questionable. But any broker that can't get more than three people to a event in London for one pf its clints must have lost interest. Avacta need to get a grip!
lantanatony
16/11/2017
17:13
Avacta Group plc ("Avacta", "the Group" or "the Company") Covance to Present Affimer Data at European Conference Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Covance will be presenting Affimer data from a joint study at the European Bioanalysis Forum 15-17 November 2017 in Barcelona. Covance will be presenting data that highlights the validation of Affimer as a critical reagent in clinical assays when good batch-to-batch stability and reproducible performance are a regulatory requirement. The work carried out collaboratively between Avacta and Covance shows that an Affimer assay to detect and quantify the breast cancer drug Trastuzumab shows good sensitivity and increased assay dynamic range compared to current existing antibody based assays. The study demonstrates that Affimer reagents have the potential to be used as alternatives to antibodies and natural ligands as critical reagents in regulated assays in the development and batch release of therapeutic antibodies. About Covance Covance Inc., a global contract research organization (CRO), is the world's most comprehensive drug development company. Covance is dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Covance also offers laboratory testing services to the chemical, agrochemical and food industries and are a market leader in toxicology services, central laboratory services, discovery services and a top global provider of Phase III clinical trial management services.
the drewster
16/11/2017
14:07
What did you think ? Any new information?
lantanatony
16/11/2017
13:59
Three of us turned up. Plus the FinnCap analyst, CEO and CFO.
the drewster
16/11/2017
13:00
All sellers today so much for yesterday's presentation to shareholders!
lantanatony
16/11/2017
12:58
All sellers today so much for yesterday's presentation to shareholders!
lantanatony
13/11/2017
10:11
Sorry ,I can't make Wednesday Anyone who is going please ask for some feed back from the market. As for Finncap,in my mind their time has come an gone. There is little or no support from them for the shares and I don't believe they have the ability to retain the confidence of the substantial shareholders. Avacta's corporate story is getting stale and without any further positive reaction from the market,what is the point of these Retail shareholder presentations?
lantanatony
11/11/2017
07:55
Anyone going on Wednesday?
the drewster
08/11/2017
20:54
No support from for the share price from the market or our Brokers even at this low share price. Meanwhile, there seems to be at least one substantial seller about. Therefore, what is the point of our CEO presenting at a Finncap event this month when the hosts are not convinced? I have to ask, what party is insisting on the confidentiality in the deals that Avacta have published? Could it be Avacta are wanting to hide from the deal detail?! Can the whole Big Pharma investing sector be wrong to ignore Avacta? The share price says it all.
lantanatony
03/11/2017
17:19
Reading this discussion, it seems that Avacta has bought a lot of different early stage technologies over the years that have not really worked out. They now seem to be back filling with "Affimers" as the latest throw of the dice, which is a big ask I suspect. Two years away from the clinic and not enough cash to get there is a real worry. The current revenue projections are not exciting and the company seems to be run as a series of academic projects. Not one for me, I'm afraid.
dj56
03/11/2017
17:06
Reading this discussion, it seems that Avacta has bought a lot of different early stage technologies over the years that have not really worked out. They now seem to be back filling with "Affimers" as the latest throw of the dice, which is a big ask I suspect. Two years away from the clinic and not enough cash to get there is a real worry. The current revenue projections are not exciting and the company seems to be run as a series of academic projects. Not one for me........
dj56
30/10/2017
08:45
MrAngry2, I've been looking to invest in a phage display technology platform company like Avacta and there are quite a few to choose from. The technology seems sound and backed by peer-reviewed publications but commercial traction seems to have been slow compared with other companies out there. Prof Smith has strong track record as an academic physicist but this is his first attempt at anything commercial. From the videos he seems very enthusiastic and engaging fellow but the strategy seems to be a bit of a scatter-gun approach: let's try everything all at once! I'm a patient investor like you but this Company looks like a typical academic start up. Have I missed anything here? I see you have all been following this company for years. Many thanks for your advice.
mj747
27/10/2017
10:52
How can you expect a life science company to produce revenue without doing years and years of research? That's the way things are I'm afraid. If you haven't got the patience for that, then I suggest you invest elsewhere.
mrangry2
26/10/2017
21:16
Shares down again today! With no support from our Market Marketer's . Therefore, Perhaps Alistair Smith should stop doing these meaningless investor presentations and get on with producing some meaningful revenue. Bonzo is correct, The management at Avacta need to get on with it or butt out! They have had plenty of time. In my view our main shareholder is the problem.....IP Group . It seems they have overloaded Avacta with loads of questionable stuff.... Long term investors have been subjected to dilution on many occasions because of this. The Avacta CEO may be Ok,but the rest of the Board seem to be poor. Avacta keep making allsorts of appointments to the Board and their key staff but it seems none of these appointments bring a anything to the revenue stream. Have an in-depth look at IP Group,just consider what they have transferred into Avacta over time,You may be Surprised to find just how many millions of their VALUE that turns out to be!
lantanatony
24/10/2017
15:13
Bonzo Lets say they are very well paid management in my opinion performing very badly.
poacher45
24/10/2017
14:53
Too many missed targets/goals to list, year after year! Collaborations that come to nothing, plus the strategy has changed more times than I care to remember. Interesting to learn that there will indeed be another fund raise, which some said would not be required. Same old story, over and over again!
wan
24/10/2017
13:47
Poacher are you suggesting that badly paid management performs better than well paid management? Which is more likely to succeed? Bsdly paid management or well paid management? The management costs are small compared with the cost of running the business... pay them well and make them deliver!
bonzo
24/10/2017
13:30
Poacher45 has his view,others may differ. But one thing is for sure Therapeutics is a big boys game! Management and the right financial support are key even if you get very lucky. Finncap and the like wont get Avacta into the true therapeutic space. They need a deal with a significant player then the shares will move. Be lucky.
lantanatony
Chat Pages: 141  140  139  138  137  136  135  134  133  132  131  130  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20171120 07:38:08